Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anupa K Arora

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 13, 2025
Development and Validation of a <sup>18</sup>F-Flortaucipir PET Visual Stratification MethodIlke Tunali, Jian Wang, Anupa K Arora, et al.
Neuroimage. Clinical|March 18, 2025
A practical overview of the use of amyloid-PET Centiloid values in clinical trials and researchLeonardo Iaccarino, Samantha C Burnham, Ilke Tunali, et al.
Dementia and Geriatric Cognitive Disorders|January 9, 2016
Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use CriteriaMichael Grundman, Keith A Johnson, Ming Lu, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 16, 2019
Clinical and cortical decline in the aphasic variant of Alzheimer's diseaseEmily Joy Rogalski, Jaiashre Sridhar, Adam Martersteck, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 15, 2026
Interchangeability of CSF and PET to identify Alzheimer's disease pathologySamantha C Burnham, Anupa K Arora, Leonardo Iaccarino, et al.
Alzheimer'S & Dementia (New York, N. Y.)|August 21, 2023
Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's diseaseSergey Shcherbinin, Amanda Morris, Ixavier A Higgins, et al.
Brain : a Journal of Neurology|January 13, 2017
Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognitionMichael J Pontecorvo, Michael D Devous, Michael Navitsky, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 9, 2017
Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imagingMichael J Pontecorvo, Anupa K Arora, Marybeth Devine, et al.
Alzheimer Disease and Associated Disorders|December 4, 2012
Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive declineMichael Grundman, Michael J Pontecorvo, Stephen P Salloway, et al.
JAMA Neurology|February 15, 2021
Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical TrialsMing Lu, Michael J Pontecorvo, Michael D Devous, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 13, 2025
Development and Validation of a <sup>18</sup>F-Flortaucipir PET Visual Stratification MethodIlke Tunali, Jian Wang, Anupa K Arora, et al.
Neuroimage. Clinical|March 18, 2025
A practical overview of the use of amyloid-PET Centiloid values in clinical trials and researchLeonardo Iaccarino, Samantha C Burnham, Ilke Tunali, et al.
Dementia and Geriatric Cognitive Disorders|January 9, 2016
Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use CriteriaMichael Grundman, Keith A Johnson, Ming Lu, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 16, 2019
Clinical and cortical decline in the aphasic variant of Alzheimer's diseaseEmily Joy Rogalski, Jaiashre Sridhar, Adam Martersteck, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 15, 2026
Interchangeability of CSF and PET to identify Alzheimer's disease pathologySamantha C Burnham, Anupa K Arora, Leonardo Iaccarino, et al.
Alzheimer'S & Dementia (New York, N. Y.)|August 21, 2023
Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's diseaseSergey Shcherbinin, Amanda Morris, Ixavier A Higgins, et al.
Brain : a Journal of Neurology|January 13, 2017
Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognitionMichael J Pontecorvo, Michael D Devous, Michael Navitsky, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 9, 2017
Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imagingMichael J Pontecorvo, Anupa K Arora, Marybeth Devine, et al.
Alzheimer Disease and Associated Disorders|December 4, 2012
Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive declineMichael Grundman, Michael J Pontecorvo, Stephen P Salloway, et al.
JAMA Neurology|February 15, 2021
Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical TrialsMing Lu, Michael J Pontecorvo, Michael D Devous, et al.
Pageof 2